Zobrazeno 1 - 10
of 399
pro vyhledávání: ''
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was condu
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes
Autor:
Robert A. Wolff, Ching Wei D. Tzeng, Michael J. Overman, Chirayu Mohindroo, Shubham Pant, Milind Javle, Wenli Dong, Gauri R. Varadhachary, Michael T. Lotze, Matthew H.G. Katz, Merve Hasanov, David R. Fogelman, Seyda Baydogan, Jane E. Rogers, Florencia McAllister, Michael P. Kim, Jonathan D. Mizrahi, Laura R. Prakash
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5041-5050 (2021)
Cancer Medicine
Cancer Medicine
Recent studies defined a potentially important role of the microbiome in modulating pancreatic ductal adenocarcinoma (PDAC) and responses to therapies. We hypothesized that antibiotic usage may predict outcomes in patients with PDAC. We retrospective
Autor:
Kimihiro Yamashita, Junko Mukohyama, Tetsu Nakamura, Gosuke Takiguchi, Kouta Yamada, Kyosuke Agawa, Shingo Kanaji, Mitsugu Fujita, Taro Oshikiri, Yoshihiro Kakeji, Satoshi Suzuki, Masafumi Saito, Hiroshi Hasegawa, Naoki Urakawa, Akihiro Watanabe, Takeru Matsuda, Akio Nakagawa
Publikováno v:
Anticancer Research. 41:4117-4126
Background/aim Cancer stem cells (CSCs) contribute to resistance against neoadjuvant chemotherapy (NAC) in esophageal squamous cell carcinoma (ESCC). We conducted a retrospective observational study for the relationship between the expression levels
Autor:
Shengmin Chen, Weifeng Wang, Huanliang Wu, Feng Yuan, Zhiren Lin, Gang Cheng, Shaohua Peng, Yunxiu Luo
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2913-2922
Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognos
Autor:
Julia Schollbach, Nicolas Schlegel, Ingo Klein, Matthias Kelm, Friedrich Anger, Stefan Löb, Volker Kunzmann, Christoph-Thomas Germer, Armin Wiegering
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefore, the goal of this retrospective study was to investigate the impact of periop
Autor:
Takeru Wakatsuki, Mariko Ogura, Keisho Chin, Hiroki Osumi, Daisaku Kamiimabeppu, Izuma Nakayama, Daisuke Takahari, Taro Sato, Akira Ooki, Eiji Shinozaki, Kensei Yamaguchi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 2, Pp 615-625 (2021)
Cancer Medicine, Vol 10, Iss 2, Pp 615-625 (2021)
Background Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Autor:
Takashi Kojima, Satoshi Fujii, Hiroyuki Daiko, Hisanaga Nomura, Tomonori Yano, Toshikatsu Kawasaki, Ken Demachi, Nobuo Mochizuki, Daiki Tsuji, Haruki Matsuzawa, Kunihiko Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:315-324
The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chem
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 16, Pp 5881-5888 (2020)
Cancer Medicine, Vol 9, Iss 16, Pp 5881-5888 (2020)
Purpose Few studies have reported the impact of the clinical response of patients with Esophageal Carcinoma to chemoradiotherapy (CRT). Our study examines the association between clinical response and pretreatment variables, survival, patterns of fai